- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
Thankyou for your answer, I belive that it is in us $…and I know that it never goes as you wish in biotech….
This is a tuff question. It depends on Apaziquone and Belinostat data. I can talk about what i expect if everything go straight trough. But as you know, it never does this in biotech.
If Apaziquone and Belinostat are good and approved in 2013, and Zevalin sales rises with Fusilev. I can se 50 in 2013, 100 in 2014 and maybe 200 in 2015. If Belinostat in CUP get approved after this phase II or gets significant off label sales it can be better. but again, its blueskye
Good work, what is your target in 1,2 and 3 years.